Oncoscience

SCIENTIFIC PUBLICATION WITH NEWSPAPER SPEED

HIGH QUALITY, OUTSTANDING EDITORIAL BOARD, OVERNIGHT PUBLICATION, OPEN ACCESS, PROMOTION, HIGH VISIBILITY

Oncoscience is a new peer-reviewed journal. Its mission is to cover rapidly growing field of cancer research, especially emergent topics not currently covered by other journals.

The main criteria for publication in Oncoscience is high-quality design and execution of the study, high-quality results and clear conclusions supported by the data.

Oncoscience publishes high-quality research papers in all areas of cancer research and beyond.

Latest News

10/10/2014: Oncoscience was accepted to the PubMed Central (PMC ). All published papers will appear on PMC retroactively.

02/20/2014: Introducing Oncoscience: from Oncotarget to the future

LATEST ISSUE

Current Cover of Oncoscience

Editors-in-Chief

Mikhail V. Blagosklonny Roswell Park Cancer Institute, Buffalo, NY

Dr. Blagosklonny is author of over 200 articles in peer-reviewed journals.
He is Associate Editor of Cancer Res, Cell Death Differ, Cancer Biol Ther, Autophagy, Int J Cancer, Am J Pathology, PLOS ONE and Editor-in-Chief of Cell Cycle. His research interests range from molecular and cellular biology to clinical investigations and include signal transduction, cell cycle, cellular senescence, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies Recently, he extended the study of signal transduction pathways from cancer to aging, revealing potential targets for slowing down aging and age-related diseases.

Andrei V. GudkovRoswell Park Cancer Institute, Buffalo, NY

Andrei V. Gudkov, PhD, DSci, Professor and Garman Family Chair in Cell Stress Biology, Senior Vice President for Basic Research of Roswell Park Cancer Institute (RPCI), Buffalo, NY
His academic degrees in experimental oncology and molecular biology were received in former USSR from National Cancer Center and Moscow State University. He is co-founder and Chief Scientific Officer of Cleveland BioLabs, Inc and Tartis, Inc. His area of general research interest includes drug discovery, gene discovery, molecular targets for cancer treatment.

New Members

Webster CaveneeUniversity of California, San Diego, CA

Webster Cavenee, Ph.D., Professor, member of the National Academy of Sciences, President AACR (1998), member of the Institute of Medicine, layreat of numerous highest awards. Webster Cavenee is director of the Ludwig Institute for Cancer Research, San Diego, and distinguished professor at the University of California, San Diego. Department of Cellular & Moecular Medicine, University of California, San Diego 9500 Gilman Drive, MC-0660, La Jolla, CA 92093.

Steve J. ElledgeHarvard Medical School, Boston, MA

Steve J Elledge, Ph.D., Professor, member of the National Academy of Sciences, HHMI investigator, the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School and and the Division of Genetics at the Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, Boston, MA. He has received many accolades and awards for his ground breaking research, including: the Michael E. Debakey Award for Research Excellence (2002), the American Association of Cancer Research G.H.A. Clowes Memorial Award (2001), the inaugural Paul Mark’s Prize in Cancer Research (2001), the National Academy of Sciences Award in Molecular Biology (2001), the John B. Carter, Jr. Technology Innovation Award (2002), an NIH Merit Award (2003), the Genetics Society of America Medal (2005), the Hans Sigrist International Prize of Bern University (2005), the Dickson Prize in Medicine (2010), the American Italian Cancer Foundation Prize for Scientific Excellence in Medicine (2012) and the Lewis Rosenstiel Award for Distinguished Work in Basic Medical Sciences (2013). In 2003 Dr. Elledge was also elected into the National Academy of Sciences and the American Academy of Arts and Sciences, to the American Academy of Microbiology in 2005, and the Institute of Medicine in 2006.

John T. IsaacsJohns Hopkins University, Baltimore, MD

John T. Isaacs, Ph.D., Professor of Oncology and Urology, Johns Hopkins Medical Institutions, Johns Hopkins University School of Medicine, Baltimore, MD

Donald W. KufeHarvard Medical School, Boston, MA

Donald W. Kufe, MD, Professor, Department of Medicine, Harvard Medical School Leader, Translational Pharmacology and Early Therapeutic Trials Program, Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute, 450 Brookline Avenue Boston, MA, 02215

Charles J. SherrSt. Jude Children's Research Hospital, Memphis, TN

Charles J. Sherr, M.D., Ph.D., Professor, member of the National Academy of Sciences, Chair, Tumor Cell Biology, Investigator, Howard Hughes Medical Institute, St. Jude Children's Research Hospital, 262 Danny Thomas Place Memphis, Tennessee 38105. He has received numerous awards: American Academy of Arts and Sciences, American-Italian Cancer Foundation Prize, American Association for the Advancement of Science, the US Institute of Medicine, General Motors Cancer Foundation Mott Prize, AACR Landon Prize for Basic Cancer Research, Bristol Myers-Squibb Achievement Award for Basic Cancer Research, AACR Pezcoller Award

David SidranskyJohns Hopkins University, Baltimore, MD

David Sidransky, M.D., Professor of Otolaryngology, Oncology, Pathology, Urology. Director, Head and Neck Cancer Research, Johns Hopkins Medical Institutions, Baltimore, MD. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world, in the field of oncology during the past decade, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is the chairman of Tamir and Champions Oncology and also serves on the board of Rosetta Genomics. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as Director (2005-2008) of the American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutics.

M. Celeste SimonUniv. Pennsylvania, Philadelphia, PA

M. Celeste Simon, Ph.D., Professor, Scientific Director and Investigator, Abramson Family Cancer Research Institute, Investigator, Howard Hughes Medical Institute, Professor, Cell and Developmental Biology, University of Pennsylvania, Perelman School of Medicine, 456 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160

Full Editorial Board